4 citations
,
October 2018 in “JAMA Dermatology” Ruxolitinib may help treat hair loss and symptoms in patients with chronic graft-versus-host disease.
43 citations
,
December 1993 in “Annals of internal medicine” Flutamide, a medication used for excessive hair growth, can cause severe liver damage in women.
2 citations
,
January 2023 in “SAGE Open Medical Case Reports” Stopping leflunomide healed the woman's skin ulcers.
1 citations
,
May 2025 in “The Journal of Rheumatology” Upadacitinib may help treat difficult cases of systemic lupus erythematosus.
1 citations
,
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.
10 citations
,
December 2005 in “Aktuelle Dermatologie” Alfatradiol (0.025%) is an effective and safe treatment for hair loss in both women and men.
PEGylated liposomal doxorubicin improves cancer treatment effectiveness and reduces side effects like heart damage and hair loss.
2 citations
,
October 2025 in “Frontiers in Medicine” Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.
January 2024 in “Wiadomości Lekarskie” Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.
April 2025 in “Frontiers in Pharmacology” Canagliflozin helps overcome progestin resistance in certain endometrial cancer cells.
4 citations
,
April 2024 in “Journal of Drugs in Dermatology” Ruxolitinib cream may help treat severe hair loss in children.
12 citations
,
May 2010 in “Journal of Clinical Oncology” MK-5108 is safe and shows potential against tumors, especially alone.
September 2024 in “Drugs & Therapy Perspectives” Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.
December 2023 in “International Journal of Dermatology”
2 citations
,
November 1990 in “International Journal of Dermatology” Albendazole can cause hair loss, and piroxicam can cause fixed drug eruption.
3 citations
,
March 2023 in “PubMed” The cat improved with treatment but had kidney issues from long-term allopurinol use.
32 citations
,
July 2017 in “Oncotarget” Alternating treatment with two drugs could help cells in a rapid aging disease.
Azathioprine can cause severe hair loss and low white blood cell count in lupus patients.
7 citations
,
March 2021 in “Journal of the American Academy of Dermatology” Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.
5 citations
,
December 2011 in “Vox Sanguinis” Some blood donors on teratogenic drugs may have unsafe drug levels, suggesting a need for better deferral policies.
April 2023 in “Journal of Investigative Dermatology” Radiation treatment causes skin fibrosis by increasing certain fibroblast subpopulations, but using a c-Jun inhibitor or fat grafting can reduce this effect.
1 citations
,
May 2023 in “Frontiers in Pharmacology” Genetic screening for NUDT15 polymorphisms is crucial for patients taking azathioprine, especially in Asians.
4 citations
,
January 2014 in “The Journal of urology/The journal of urology” Kidney cancer cells without folliculin are more sensitive to radiation due to increased self-eating cell death.
60 citations
,
November 2009 in “General and Comparative Endocrinology” Fadrozole and finasteride change gene expression related to sex hormones and thyroid hormones in frog larvae development.
June 2025 in “British Journal of Dermatology” Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.
August 2002 in “Dermatologic Surgery” Fluridil safely promotes hair growth in men with androgenetic alopecia.
September 2024 in “Acta Medica Philippina” Radiation from a medical procedure caused temporary hair loss, but hair regrew with treatment.
3 citations
,
November 2024 in “Clinical Research” Deuruxolitinib is FDA-approved for treating severe alopecia areata.
2 citations
,
December 2023 in “Journal of clinical immunology” Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.